Receptor status of tumor as prognostic factor in patients with bilateral breast cancer

Aim: To determine the receptor status of tumors as prognostic factor in development of bilateral breast cancer (BBC) and factor of prognosis of disease. Patients and Methods: 272 cases of BBC during the period from 1995 to 2011 in different oncological institutions of Ukraine have been analyzed. Res...

Повний опис

Збережено в:
Бібліографічні деталі
Опубліковано в: :Experimental Oncology
Дата:2013
Автори: Tsyhyka, D.Y., Hotko, Y.S., Devinyak, O.T.
Формат: Стаття
Мова:Англійська
Опубліковано: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2013
Теми:
Онлайн доступ:https://nasplib.isofts.kiev.ua/handle/123456789/145263
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
Назва журналу:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Цитувати:Receptor status of tumor as prognostic factor in patients with bilateral breast cancer / D.Y. Tsyhyka, Y.S. Hotko, O.T. Devinyak // Experimental Oncology. — 2013. — Т. 35, № 4. — С. 291-294. — Бібліогр.: 11 назв. — англ.

Репозитарії

Digital Library of Periodicals of National Academy of Sciences of Ukraine
_version_ 1860255004001042432
author Tsyhyka, D.Y.
Hotko, Y.S.
Devinyak, O.T.
author_facet Tsyhyka, D.Y.
Hotko, Y.S.
Devinyak, O.T.
citation_txt Receptor status of tumor as prognostic factor in patients with bilateral breast cancer / D.Y. Tsyhyka, Y.S. Hotko, O.T. Devinyak // Experimental Oncology. — 2013. — Т. 35, № 4. — С. 291-294. — Бібліогр.: 11 назв. — англ.
collection DSpace DC
container_title Experimental Oncology
description Aim: To determine the receptor status of tumors as prognostic factor in development of bilateral breast cancer (BBC) and factor of prognosis of disease. Patients and Methods: 272 cases of BBC during the period from 1995 to 2011 in different oncological institutions of Ukraine have been analyzed. Results: Patients with metachronous BBC with positive status of hormone receptors (HR) of tumors have significantly better indices of overall and progression-free survival (three-years — 95%, five-years — 72%), than patients with HR-negative status (among them nobody has survived over 5 years). In patients with synchronous BBC, the receptor status of tumors has similar influence on the prognosis of survival. Nevertheless, indices of overall survival (65%) and progression-free survival (66%) in HR-positive patients were lower than that at metachronous BBC (overall survival and progression-free survival — 72%). Conclusions: Synchronous breast cancer has more aggressive clinical course than metachronous one. It was determined significant influence of receptor status of tumors on the overall survival and progression-free survival in patients with BBC.
first_indexed 2025-12-07T18:48:09Z
format Article
fulltext
id nasplib_isofts_kiev_ua-123456789-145263
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
issn 1812-9269
language English
last_indexed 2025-12-07T18:48:09Z
publishDate 2013
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
record_format dspace
spelling Tsyhyka, D.Y.
Hotko, Y.S.
Devinyak, O.T.
2019-01-20T08:21:52Z
2019-01-20T08:21:52Z
2013
Receptor status of tumor as prognostic factor in patients with bilateral breast cancer / D.Y. Tsyhyka, Y.S. Hotko, O.T. Devinyak // Experimental Oncology. — 2013. — Т. 35, № 4. — С. 291-294. — Бібліогр.: 11 назв. — англ.
1812-9269
https://nasplib.isofts.kiev.ua/handle/123456789/145263
Aim: To determine the receptor status of tumors as prognostic factor in development of bilateral breast cancer (BBC) and factor of prognosis of disease. Patients and Methods: 272 cases of BBC during the period from 1995 to 2011 in different oncological institutions of Ukraine have been analyzed. Results: Patients with metachronous BBC with positive status of hormone receptors (HR) of tumors have significantly better indices of overall and progression-free survival (three-years — 95%, five-years — 72%), than patients with HR-negative status (among them nobody has survived over 5 years). In patients with synchronous BBC, the receptor status of tumors has similar influence on the prognosis of survival. Nevertheless, indices of overall survival (65%) and progression-free survival (66%) in HR-positive patients were lower than that at metachronous BBC (overall survival and progression-free survival — 72%). Conclusions: Synchronous breast cancer has more aggressive clinical course than metachronous one. It was determined significant influence of receptor status of tumors on the overall survival and progression-free survival in patients with BBC.
en
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
Experimental Oncology
Special issue on breast cancer
Receptor status of tumor as prognostic factor in patients with bilateral breast cancer
Article
published earlier
spellingShingle Receptor status of tumor as prognostic factor in patients with bilateral breast cancer
Tsyhyka, D.Y.
Hotko, Y.S.
Devinyak, O.T.
Special issue on breast cancer
title Receptor status of tumor as prognostic factor in patients with bilateral breast cancer
title_full Receptor status of tumor as prognostic factor in patients with bilateral breast cancer
title_fullStr Receptor status of tumor as prognostic factor in patients with bilateral breast cancer
title_full_unstemmed Receptor status of tumor as prognostic factor in patients with bilateral breast cancer
title_short Receptor status of tumor as prognostic factor in patients with bilateral breast cancer
title_sort receptor status of tumor as prognostic factor in patients with bilateral breast cancer
topic Special issue on breast cancer
topic_facet Special issue on breast cancer
url https://nasplib.isofts.kiev.ua/handle/123456789/145263
work_keys_str_mv AT tsyhykady receptorstatusoftumorasprognosticfactorinpatientswithbilateralbreastcancer
AT hotkoys receptorstatusoftumorasprognosticfactorinpatientswithbilateralbreastcancer
AT devinyakot receptorstatusoftumorasprognosticfactorinpatientswithbilateralbreastcancer